Presynaptic Muscarinic Receptors: Change of Sensitivity During Long-Term Drug Treatment

  • M. Marchi
  • M. Raiteri
Part of the Advances in Behavioral Biology book series (ABBI, volume 30)


It is widely accepted that the sensitivity of neurotransmitter receptors can be modified during long-term activation or blockade of these receptors by specific drugs. Desensitization of receptors occurs in general after long-lasting exposure to agonists, whereas reduced supply of the agonist transmitter to its receptors, as in the case of a chronic treatment with antagonist drugs, appears to cause receptor supersensitivity. These modifications of receptor sensitivity are likely to have important implications, both in the ethiology of some diseases of the nervous system and in the mechanism of action of drugs used in the treatment of these disorders. In view of these considerations, it is important to ascertain whether and in what conditions a given receptor system can undergo adaptive changes, since neurotransmitter receptors may not be all equally adaptable.


Release Curve Neurotransmitter Receptor Muscarinic Receptor Subtype Receptor Supersensitivity Cortical Synaptosome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Frankhuyzen, A.L. and Mulder, A.H. (1982): Eur. J. Pharmacol. 81: 97–106.CrossRefGoogle Scholar
  2. 2.
    Lehmann, J. and Langer, S.Z. (1982): Brain Res. 248: 61–69.CrossRefGoogle Scholar
  3. 3.
    Lehmann, J., Smith, R.V. and Langer, S.Z. (1983): Eur. J. Pharmacol. 88: 81–88.CrossRefGoogle Scholar
  4. 4.
    Molenaar, P.C. and Polak, R.L. (1970): Br. J. Pharmacol. 40: 406–417.Google Scholar
  5. 5.
    Marchi, M., Paudice, P. and Raiteri, M. (1981): Eur. J. Pharmacol. 73: 75–79.CrossRefGoogle Scholar
  6. 6.
    Marchi, M., Paudice, P., Caviglia, A. and Raiteri, M. (1983): Eur. J. Pharmacol. 91: 63–68.CrossRefGoogle Scholar
  7. 7.
    Nordstrom, 0. and Bartfai, T. (1980); Acta Physiol. Scand. 108: 347–353.CrossRefGoogle Scholar
  8. 8.
    Raiteri, M., Angelini, F. and Levi, G. (1974): Eur. J. Pharmacol. 25: 411–414.CrossRefGoogle Scholar
  9. 9.
    Raiteri, M., Marchi, M. and Maura, G. (1982): Eur. J. Pharmacol. 83: 127–129.CrossRefGoogle Scholar
  10. 10.
    Raiteri, M., Maura, G. and Versace, P. (1983): J. Pharmacol. Exp. Ther. 224: 679–684.Google Scholar
  11. 11.
    Raiteri, M., Leardi, R. and Marchi, R. (1984): J. Pharmacol. Exp. Ther. 228: 209–214.Google Scholar
  12. 12.
    Rospars, J.P., Lefresne, P., Beaujouan, J.C. and Glowinski, J. (1977): Naunyn-Schmied. Arch. Pharmacol. 300: 153–161.CrossRefGoogle Scholar
  13. 13.
    Szerb, J.C. (1977): In Cholinergic Mechanisms and Psychopharmacology (ed) D.J. Jenden, Plenum Press, New York, pp. 49–60.Google Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • M. Marchi
    • 1
  • M. Raiteri
    • 1
  1. 1.Institute of Pharmacology and PharmacognosyUniversity of GenovaGenovaItaly

Personalised recommendations